Navigation Links
Stereotaxis Reports Third Quarter Financial Results

ST. LOUIS, Nov. 7, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today reported financial results for the third quarter ended September 30, 2011.  

Third Quarter 2011 Financial ResultsRevenue for the third quarter was $8.5 million, down 38% from the year ago period.  The decrease was primarily due to softness in Niobe® robotic system sales, resulting from market demand for a more efficient solution for complex ablation procedures and the ongoing platform transition from Niobe II to the Company's new Epoch™ platform.  The Company recognized revenue on one Niobe system and $1.0 million in Odyssey™ systems in the third quarter.  Recurring revenue in the quarter was $6.5 million, a 14% increase from the year-ago quarter.  This growth was attributable to the larger installed base of Niobe systems and increased utilization leading to greater disposable sales and service contracts over last year, as well as favorable pricing.  

The Company generated global new capital orders of $2.2 million in the third quarter, which were comprised of four upgrades to the Epoch platform from Niobe II, two Vdrive™ robotic navigation systems, and $1.6 million in orders related to Odyssey.  

"Our top-line performance and system orders in the quarter, as we expected, were impacted by market demand for a more efficient solution for complex ablation procedures and the ongoing platform transition from Niobe II to Epoch," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  "These factors contributed to softness in Niobe II revenue and the related impact on Odyssey installations in Niobe labs.  Meanwhile, we continue to build market momentum and interest in the Epoch platform ahead of its planned launch in December.  We remain encouraged by the early, positive market feedback, which indicates that Epoch's much improved efficiency and technological enhancements could regenerate market demand for magnetic robotics in electrophysiology procedures.  We are focused on driving rapid market adoption of the Epoch platform, and reaffirm our plan for initial shipments to customers before the end of this year."

Kaminski continued, "We are taking actions that we believe will provide us with the necessary financial resources to capitalize on our growth opportunities.  Our operating expense reduction continues, and we expect to see the initial impact beginning in the fourth quarter 2011, with full realization of a 15% to 20% reduction in annualized year-to-date September 30, 2011 operating expenses by the beginning of 2012.   In addition, we anticipate completing a non-equity capital raise by November 30, 2011, which would satisfy our obligation under the Fourth Loan Modification Agreement with Silicon Valley Bank."

Gross margin was $5.9 million, or 68.9% of net revenue, including a $0.5 million charge related to the absorption of overhead costs based on normal production levels.  Before the charge, gross margin in the quarter was 74.3% compared to $10.0 million, or 72.2% of net revenue in the year ago quarter.  The improvement in gross margin as a percent of net revenue prior to this charge was due to a higher mix of recurring revenue in the 2011 third quarter.

Operating expenses were $14.9 million in the third quarter, an increase of 10% compared to the $13.6 million in the year ago period.  The increase was primarily due to higher research and development expenditures related to the Niobe Epoch and Odyssey upgrades, increased spending on registrations in Japan and foreign currency exchange losses as the U.S. dollar strengthened against the Euro.  

The net loss for the third quarter was $(7.3) million, or $(0.13) per share, compared to a net loss of $(5.1) million, or $(0.10) per share, reported for the third quarter 2010.  The weighted average shares outstanding for the third quarter of 2011 totaled 54.9 million, compared with 50.1 million in the third quarter of 2010.  The increase in shares outstanding was due in large part to the issuance of 4.6 million shares as part of the stock offering completed in November 2010.

At September 30, 2011, Stereotaxis had cash and cash equivalents of $17.0 million, compared to $23.3 million on June 30, 2011.  Total debt was $29.0 million, including $16.9 million drawn against the Company's $20 million line of credit.  Cash burn for the third quarter 2011 was $6.4 million.

Rebalancing Operating Expenses Around the Epoch and Odyssey PlatformsIn order to ensure the successful commercialization of the Epoch and Odyssey platforms, as well as conserve resources, Stereotaxis began implementing a wide ranging plan in the 2011 third quarter that includes rebalancing and reducing operating expenses to minimize the Company's cash burn, while continuing to fund R&D investment in key growth areas.  As of September 30, 2011, the Company has completed the majority of the operating expense reductions through headcount and discretionary spending cuts and continues to implement processes and changes to further reduce operating costs.  The Company anticipates that this will result in an operating expense reduction of 15% to 20% on a year-to-date September 30th annual run rate basis.

Non-Equity Capital RaiseOn October 11, 2011, Company entered into a non-binding term sheet with an institutional investor to raise non-equity capital.  The Company expects the capital raise to be completed by November 30, 2011, satisfying the Company's obligation under the Fourth Loan Modification Agreement with Silicon Valley Bank.  The Company and the institutional investor are working diligently and in good faith to close the transaction, subject to customary closing conditions including the negotiation and execution of mutually acceptable, definitive transaction documentation. 

Year-to-Date Financial PerformanceRevenue for the first nine months of 2011 was $30.4 million, compared to $39.5 million in the first nine months of 2010.  Gross margin was $21.2 million, or 69.8% of revenue, compared with $27.8 million, or 70.4% of revenue in the first nine months of the prior year.  Operating expenses were $48.6 million for the first nine months of 2011 compared with $43.3 million in the same period of 2010.  The net loss was $(26.5) million for the first nine months of 2011 compared with $(17.4) million for the comparable period of 2010.  Cash burn for the first nine months of 2011, including payments against the Biosense Webster advance, was $23.4 million compared with $16.0 million in the first nine months of 2010.  Stereotaxis has historically included the repayment of the Biosense advance as part of cash burn as operationally the advance is reduced by the earning of royalties.  Of the $23.4 million in year-to-date cash burn, $4.8 million is repayment of Biosense debt.

Conference Call and WebcastStereotaxis will host a conference call and webcast today, November 7, 2011 at 4:30 p.m. Eastern Time, to discuss third quarter results and operational progress.  The dial-in number for the conference call is 1-800-762-8779 for domestic participants and 1-480-629-9771 for international participants.  Participants are asked to call the above numbers 5-10 minutes prior to the starting time.  A real-time listen-only webcast of the conference call will be accessible at, in the "Investor Relations" section under "Event Calendar."  Listeners should go to the website at least 15 minutes prior to the live conference call to install any necessary audio software.  

An audio replay of the call will be available for seven days following the call, and can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4484029#.  The call will also be available on the Internet live and for 90 days thereafter at

About Stereotaxis
www.odysseyexperience.comStereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey Cinema™ Studio then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit and

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, our continued access to capital and financial resources, including our ability to negotiate financing and lending arrangements on terms that are acceptable, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.STEREOTAXIS, INC.BALANCE SHEETS(Unaudited)September 30,
2011December 31,
2010(Unaudited)AssetsCurrent assets:Cash and cash equivalents

,979,863$   35,248,819Accounts receivable, net of allowance of $386,153 and $367,536 in 2011 and 2010, respectively

4,533,99013,915,569Current portion of long-term receivables


5,866,5065,441,475Prepaid expenses and other current assets

3,314,8104,557,718Total current assets

30,759,44059,194,381Property and equipment, net

3,634,1853,840,622Intangible assets

2,354,1112,578,986Long-term receivables

81,514109,266Other assets

41,82138,537Total assets

36,871,071$   65,761,792Liabilities and stockholders' equity (deficit)Current liabilities:   Current maturities of long-term debt

28,992,163$   20,894,091   Accounts payable

7,006,4958,796,182   Accrued liabilities

6,153,0886,966,571   Deferred contract revenue

8,180,8016,600,313   Warrants

289,9763,541,798Total current liabilities

50,622,52346,798,955Long-term debt, less current maturities

-8,000,000Long-term deferred contract revenue

335,296478,850Other liabilities

3,0948,741Stockholders' equity (deficit):Preferred stock, par value $0.001; 10,000,000 shares authorized at 2011 and 2010; none outstanding at 2011 and 2010

--Common stock, par value $0.001; 100,000,000 shares authorized at 2011 and 2010; 55,408,312 and 54,746,240 issued at 2011 and 2010, respectively

55,40854,746   Additional paid-in capital

355,954,708354,002,770   Treasury stock, 40,151 shares at 2011 and 2010

(205,999)(205,999)   Accumulated deficit

(369,893,959)(343,376,271)Total stockholders' equity (deficit)

(14,089,842)10,475,246Total liabilities and stockholders' equity (deficit)

36,871,071$   65,761,792STEREOTAXIS, INC.STATEMENTS OF OPERATIONS(Unaudited)Three Months Ended

September 30,Nine Months Ended
September 30,2011201020112010Revenue   System

22,826,700   Disposables, service and accessories

6,506,2725,719,16619,020,39616,680,241Total revenue

8,544,01413,872,25430,370,85739,506,941Cost of revenue   System

1,723,8743,091,7346,428,7839,482,225   Disposables, service and accessories

933,380763,3482,749,7962,219,680Total cost of revenue

2,657,2543,855,0829,178,57911,701,905Gross margin

5,886,76010,017,17221,192,27827,805,036Operating expenses:Research and development

3,529,3212,868,42610,234,7579,595,972Sales and marketing

6,885,7867,269,00524,936,64122,410,734General and administration

4,527,4893,471,24413,384,31311,337,637Total operating expenses

14,942,59613,608,67548,555,71143,344,343Operating loss

(9,055,836)(3,591,503)(27,363,433)(15,539,307)Other income (expense)

2,611,067(920,222)3,251,82249,830Interest income

1,8173,0047,1377,934Interest expense

(830,118)(635,176)(2,413,214)(1,951,098)Net loss

$   (7,273,070)$   (5,143,897)$
(17,432,641)Net loss per common share:   Basic and diluted

(0.35)Weighted average shares used in computing net
loss per common share: Basic and diluted


SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
2. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
3. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
4. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
5. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
7. Stereotaxis to Report Second Quarter 2011 Financial Results and Conduct Conference Call on August 8, 2011
8. Stereotaxis and Biosense Webster Announce New Strategic Collaboration
9. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
10. Stereotaxis Reports First Quarter 2011 Financial Results
11. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
Post Your Comments:
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):